ProPhase Labs Reports Financial Results for the Three and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ProPhase Labs Reports Financial Results for the Three and Nine Months Ended September 30, 2015

DOYLESTOWN, PA--(Marketwired - Nov 12, 2015) - ProPhase Labs, Inc. ( NASDAQ : PRPH ) ( www.ProPhaseLabs.com ) today reported its net sales were $4.4 million for the three months ended September 30, 2015, as compared to net sales of $5.1 million for the three months ended September 30, 2014. The Company realized net income for the three months ended September 30, 2015 of $602,000, or $0.04 per share, compared to a net loss of $3.2 million, or ($0.18) per share, for the three months ended September 30, 2014. 

The Company's sales are principally derived from its over-the-counter ("OTC") health care and cold remedy products. As a consequence, a significant portion of our business is highly seasonal, which causes significant variations in operating results from quarter to quarter. 

Results for the third quarter of 2015 compared to the third quarter of 2014 principally reflect the net effect of (i) a decrease in net sales of $740,000, (ii) a decrease in administration costs of $695,000 due principally to a decrease in professional and legal costs related to certain, now resolved, litigation matters, (iii) a decrease in sales and marketing expenses of $176,000, (iv) a decrease in research and development expenditures of $161,000 and (v) non-recurring impairment charge to operations of $3.6 million during the third quarter of 2014. 

The Company generated net sales for the nine months ended September 30, 2015 of $12.4 million, as compared to $13.1 million for the nine months ended September 30, 2014. The Company incurred a net loss for the nine months ended September 30, 2015 of $2.3 million, or ($0.14) per share, compared to a net loss of $7.2 million, or ($0.42) per share, for the nine months ended September 30, 2014.

The financial results for the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014 reflect the net effect of (i) a decrease in net sales of $657,000, (ii) a decrease in administration costs of $1.4 million due principally to a decrease in professional and legal costs related to certain, now resolved, litigation matters, (iii) a decrease in sales and marketing expenses of $503,000 as a consequence of the fluctuation from period to period of the timing and scope of our marketing initiatives, (iv) a decrease in research and development expenditures of $232,000, and (v) non-recurring impairment charge to operations of $3.6 million during the third quarter of 2014. 

Ted Karkus, the CEO of the Company, stated, "Our product development efforts over the past several years have been largely focused on successfully leveraging the Cold-EEZE ® brand. To this end, three new product line extensions are now available on retail shelves for the fourth quarter of 2015: (i) Cold-EEZE ® Multi-Symptom Relief for Cold and Flu lozenges, (ii) Cold-EEZE ® Daytime and Nighttime Multi-Symptom Relief in liquid forms for each of adults and children, and (iii) Cold-EEZE ®  Natural Allergy Relief caplets for indoor and outdoor allergies. Our current plan is to introduce two additional Cold-EEZE ® branded products to the trade in February of 2016."

Mr. Karkus continued, "In addition to the continued development and commercialization of new Cold-EEZE ® branded products, we are also continuing the development of the new TK Supplements line of products in the dietary supplement category. Our new product line is initially comprised of three men's health products for: (i) sexual health, (ii) daily energy booster plus testosterone support and (iii) prostate and urinary health. I am pleased to announce that the pre-commercialization steps for all three products, including formulation, stabilization, mass production and packaging are near completion. Additionally, we anticipate that our first product in this category for sexual health will be introduced to the marketplace through Direct Response TV within the next 1-2 months."

Mr. Karkus added, "While we are certainly optimistic, no assurance can be made that our new TK Supplements product efforts will be successful. Furthermore, over time we may need to raise additional funds through debt financing or equity financing to support all of these strategic initiatives and to provide additional working capital."

About ProPhase Labs ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE ® Cold Remedy brand as well as other cold relief products. Cold-EEZE ® Cold Remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold. Cold-EEZE ® Cold Remedy customers include leading national chain, regional, specialty and local retail stores. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE ® Cold Remedy lozenges and fulfill other contract manufacturing opportunities. For more information visit us at www.ProPhaseLabs.com .

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of the acceptance and demand for our products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings

 
PROPHASE LABS, INC. & SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)
             
    Three Months Ended     Nine Months Ended  
    September 30, 2015     September 30, 2014     September 30, 2015     September 30, 2014  
                                 
Net sales   $ 4,390     $ 5,130     $ 12,441     $ 13,098  
                                 
Cost of sales     1,671       1,620       5,052       4,816  
                                 
Gross profit     2,719       3,510       7,389       8,282  
                                 
Operating expenses:                                
  Sales and marketing     699       875       4,221       4,724  
  Administration     1,222       1,917       4,834       6,228  
  Research and development     195       356       675       907  
  Impairment charge     -       3,577       -       3,577  
      2,116       6,725       9,730       15,436  
                                 
Income (loss) from operations     603       (3,215 )     (2,341 )     (7,154 )
                                 
Interest income, net     (1 )     (1 )     (3 )     (4 )
                                 
Income (loss) before income tax     602       (3,216 )     (2,344 )     (7,158 )
                                 
Income tax     -       -       -       -  
                                 
Net income (loss)   $ 602     $ (3,216 )   $ (2,344 )   $ (7,158 )
                                 
Basic income (loss) per share:                                
Net income (loss)   $ 0.04     $ (0.18 )   $ (0.14 )   $ (0.42 )
                                 
Diluted income (loss) per share:                                
Net income (loss)   $ 0.04     $ (0.18 )   $ (0.14 )   $ (0.42 )
                                 
Weighted average common                                
shares outstanding:                                
  Basic     16,597       18,208       16,171       17,216  
  Diluted     16,972       18,208       16,171       17,216  
                                   
                                   
 
PROPHASE LABS, INC. & SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(in thousands)
(unaudited)
 
         
    September 30,   December 31,
    2015   2014
             
Cash and cash equivalents   $ 1,336   $ 2,926
Accounts receivable   $ 2,766   $ 5,836
Inventory   $ 4,891   $ 3,292
Total current assets   $ 10,835   $ 13,458
Total assets   $ 13,852   $ 16,057
             
Total current liabilities   $ 3,715   $ 5,241
Other long term obligations   $ 100   $ 100
Total stockholders' equity   $ 10,037   $ 10,716
             
             

Press Only Contact Constantine Panagiotatos DKC Public Relations Tel: (212) 981-5124 Constantine_Panagiotatos@dkcnews.com Investor Contact Ted Karkus Chairman and CEO ProPhase Labs, Inc. (215) 345-0919 x 0

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 64

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 68

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Senior Living: The BrainFit Gym Experience

Updated Category News Views 330

Introducing the BrainFit Gym at The Bristal The Bristal Assisted Living is taking a bold step towards promoting cognitive wellness among seniors with their newly launched BrainFit Gym. Located at The Bristal at York Avenue, this unique facility stands out as a pioneering initiative aimed at enhancing the mental capacities of its residents. With this innovative approach,...

Continue Reading
Bullish (BLSH) Stock Surges After Thrilling IPO Success

Updated Category News Views 262

Bullish Stock Makes a Remarkable Entrance on the Market Recently, the cryptocurrency exchange Bullish (BLSH) took the public market by storm with its much-anticipated initial public offering (IPO). Its shares soared following trading debut, generating excitement among investors and analysts alike. Key Highlights of the IPO Supported by the renowned billionaire venture...

Continue Reading
Medius Honored as Top Microsoft Partner for Innovative Finance

Updated Category News Views 118

Medius Named 2024 Microsoft ISV Partner of the Year Medius, a leader in Accounts Payable (AP) Automation and Spend Management solutions, has reached an impressive milestone by being honored as the 2024 Microsoft ISV Partner of the Year. This esteemed award showcases Medius' dedication to innovation and excellence in improving finance operations through technology. The...

Continue Reading
Day One Biopharmaceuticals Set to Reveal Q1 2025 Financials

Updated Category News Views 309

Day One Biopharmaceuticals Plans Q1 2025 Financial Report Day One Biopharmaceuticals (NASDAQ: DAWN) is gearing up for a significant event. The biopharmaceutical company, known for its dedication to developing targeted therapies for serious illnesses, has announced a live conference call and webcast set for early May 2025. This event offers a chance for stakeholders to...

Continue Reading
Navigating the Future of Nonprofit Fundraising in 2025

Updated Category News Views 441

Nonprofit Fundraising Trends for 2025 As we approach the year 2025, nonprofits are setting their sights on innovative tactics that will not only enhance their fundraising efforts but also embrace the changing dynamics of donor engagement. Recent insights reveal that the landscape of nonprofit fundraising is evolving, making adaptability a core component of success in the...

Continue Reading